Parker Richard, Schmidt Mark S, Cain Owen, Gunson Bridget, Brenner Charles
Centre for Liver Research University of Birmingham Birmingham United Kingdom.
Liver and Hepatobiliary Unit University Hospitals Birmingham NHS Foundation Trust Birmingham United Kingdom.
Hepatol Commun. 2020 May 31;4(8):1183-1192. doi: 10.1002/hep4.1530. eCollection 2020 Aug.
Nicotinamide adenine dinucleotide (NAD) and related coenzymes play critical roles in liver function. Although hepatic alcohol metabolism depresses NAD, current understanding of the NAD metabolome in alcohol-related liver disease (ArLD) is based on animal models. We used human liver samples to quantify the NAD metabolome in ArLD with samples obtained at the time of liver transplantation or resection at University Hospitals Birmingham National Health Service Foundation Trust. The severity of steatohepatitis in liver from patients with ArLD was assessed with standard liver function tests and histology. NAD-targeted quantitative metabolomic analysis of liver tissue was performed by liquid chromatography-tandem mass spectrometry. Seventy-two human liver specimens were analyzed, including 43 with ArLD. The NAD metabolome differed significantly between different types of liver disease (two-way analysis of variance [ANOVA], = 0.001). ArLD liver tissue showed markedly depressed concentrations of NAD (432 μM vs. 616 μM in normal liver) and precursor molecules nicotinic acid and nicotinamide riboside. There was a significant overall difference in the NAD metabolome between ArLD samples with and without steatohepatitis (two-way ANOVA, = 0.018). After correcting for multiple comparisons, a significant difference for individual components of the metabolome was observed for the concentration of NAD (mean, 462 μM vs. 322 μM; < 0.01 in nonsevere vs. severe alcoholic steatohepatitis, respectively). NAD concentration was inversely related to serum bilirubin concentration ( = -0.127; = 0.04) and positively correlated with myeloperoxidase activity ( = 0.31; = 0.003). The concentration of NAD and its precursor molecules are significantly reduced in ArLD and are associated with disease activity. : Liver samples from people with ArLD show depressed NAD and precursor levels as well as depressed myeloperoxidase activity.
烟酰胺腺嘌呤二核苷酸(NAD)及相关辅酶在肝脏功能中发挥着关键作用。尽管肝脏酒精代谢会降低NAD水平,但目前对酒精性肝病(ArLD)中NAD代谢组的认识是基于动物模型。我们使用来自英国伯明翰大学医院国民保健服务基金会信托基金肝移植或肝切除时获取的人类肝脏样本,对ArLD中的NAD代谢组进行定量分析。通过标准肝功能测试和组织学评估ArLD患者肝脏中脂肪性肝炎的严重程度。采用液相色谱 - 串联质谱法对肝组织进行NAD靶向定量代谢组分析。共分析了72例人类肝脏标本,其中43例为ArLD。不同类型肝病之间的NAD代谢组存在显著差异(双向方差分析,P = 0.001)。ArLD肝组织中NAD(正常肝脏中为616μM,ArLD肝组织中为432μM)以及前体分子烟酸和烟酰胺核苷的浓度显著降低。有无脂肪性肝炎的ArLD样本之间的NAD代谢组存在显著总体差异(双向方差分析,P = 0.018)。在进行多重比较校正后,观察到代谢组单个成分的显著差异在于NAD浓度(平均值,非重度与重度酒精性脂肪性肝炎中分别为462μM对322μM;P < 0.01)。NAD浓度与血清胆红素浓度呈负相关(r = -0.127;P = 0.04),与髓过氧化物酶活性呈正相关(r = 0.31;P = 0.003)。ArLD中NAD及其前体分子的浓度显著降低,并与疾病活动相关。ArLD患者的肝脏样本显示NAD及其前体水平降低以及髓过氧化物酶活性降低。